Clinical Trials in Bournemouth, Dorset

7 recruiting

Showing 17 of 7 trials

Recruiting
Phase 3

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Phase 3

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Follicular Lymphoma ( FL)
Regeneron Pharmaceuticals822 enrolled190 locationsNCT06091254
Recruiting
Phase 3

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Regeneron Pharmaceuticals470 enrolled168 locationsNCT06149286
Recruiting
Not Applicable

RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure

Heart Failure
University Hospital Southampton NHS Foundation Trust2,504 enrolled47 locationsNCT05568069
Recruiting
Phase 3

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 3

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Multiple Myeloma
Pfizer944 enrolled239 locationsNCT05020236
Recruiting
Phase 2

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

Breast Neoplasm
Institute of Cancer Research, United Kingdom119 enrolled6 locationsNCT03740893